Correction
Expert Opin Emerg Drugs. 2024 Apr 18:1. doi: 10.1080/14728214.2024.2342646. Online ahead of print.NO ABSTRACTPMID:38634431 | DOI:10.1080/14728214.2024.2342646 (Source: Expert Opinion on Emerging Drugs)
Source: Expert Opinion on Emerging Drugs - April 18, 2024 Category: Drugs & Pharmacology Source Type: research
Emerging monoclonal antibody therapy for head and neck squamous cell carcinoma
This article aims to review the multiple monoclonal antibodies (mAbs) regimens currently under development, targeting various growth factors, immune checkpoints, immune costimulatory receptors, and more.EXPERT OPINION: So far, the combination of anti-EGFR and ICI appears to be the most promising, especially in HPV-negative patients. It will be interesting to confirm whether the arrival of antibody-drug conjugates and bispecific mAb can surpass the efficacy of anti-EGFR, as they are also being tested in combination with ICI. Furthermore, we believe that immune costimulatory agonists and various ICIs combination are worth mo...
Source: Expert Opinion on Emerging Drugs - April 15, 2024 Category: Drugs & Pharmacology Authors: Francis Proulx-Rocray Denis Souli ères Source Type: research
Emerging drugs in phase II and III clinical development for the treatment of alcohol use disorder
Expert Opin Emerg Drugs. 2024 Apr 12. doi: 10.1080/14728214.2024.2342951. Online ahead of print.ABSTRACTINTRODUCTION: Alcohol Use Disorder (AUD) poses an ongoing significant global health burden. AUD is highly prevalent and affects not only the individuals with AUD, but also their communities and society at large. Even though pharmacotherapy is an integral part of AUD treatment, the few available substances show limited efficacy and limited clinical impact. Thus, there is a need for new innovative pharmacotherapeutic approaches.AREAS COVERED: This paper provides a comprehensive review of drugs approved for the treatment of...
Source: Expert Opinion on Emerging Drugs - April 12, 2024 Category: Drugs & Pharmacology Authors: Sophie K öhne Thomas Hillemacher Alexander Glahn Patrick Bach Source Type: research
Evolving role of viadisc for chronic low back and discogenic pain: a narrative review
Expert Opin Emerg Drugs. 2024 Apr 11. doi: 10.1080/14728214.2024.2339912. Online ahead of print.ABSTRACTINTRODUCTION: Chronic lower back pain is a leading cause of disability and healthcare spending worldwide. Discogenic pain, pain originating from the intervertebral disk, is a common etiology of chronic lower back pain. Currently, accepted treatments for chronic discogenic pain focus only on the management of symptoms, such as pain. There are no approved treatments that stop or reverse degenerating intervertebral discs. Biologic therapies promoting disc regeneration have been developed to expand treatment options. VIADISC...
Source: Expert Opinion on Emerging Drugs - April 11, 2024 Category: Drugs & Pharmacology Authors: Jack K Tolson Robert L Menuet Gianni H Ly Benjamin A Chanes Elizabeth A Bryan Saurabh Kataria Julian Kim Shahab Ahmadzadeh Sahar Shekoohi Alan D Kaye Source Type: research
Emerging synthetic drugs for the treatment of hepatic cirrhosis: a 2024 update
Expert Opin Emerg Drugs. 2024 Apr 11. doi: 10.1080/14728214.2024.2341878. Online ahead of print.NO ABSTRACTPMID:38603460 | DOI:10.1080/14728214.2024.2341878 (Source: Expert Opinion on Emerging Drugs)
Source: Expert Opinion on Emerging Drugs - April 11, 2024 Category: Drugs & Pharmacology Authors: Jonathan A Fallowfield Maria Jimenez Ramos Source Type: research
Emerging drugs for the treatment of herpetic keratitis
Expert Opin Emerg Drugs. 2024 Apr 11:1-14. doi: 10.1080/14728214.2024.2339899. Online ahead of print.ABSTRACTINTRODUCTION: Herpes simplex keratitis stands as a prominent factor contributing to infectious blindness among developed nations. On a global scale, over 60% of the population tests positive for herpes simplex virus type-1 (HSV-1). Despite these statistics, there is currently no vaccine available for the virus. Moreover, the conventional nucleoside drugs prescribed to patients are proving ineffective in addressing issues related to drug resistance, recurrence, latency, and the escalating risk of vision loss. Hence, ...
Source: Expert Opinion on Emerging Drugs - April 11, 2024 Category: Drugs & Pharmacology Authors: Divya Kapoor Pankaj Sharma Deepak Shukla Source Type: research
Evolving role of viadisc for chronic low back and discogenic pain: a narrative review
Expert Opin Emerg Drugs. 2024 Apr 11. doi: 10.1080/14728214.2024.2339912. Online ahead of print.ABSTRACTINTRODUCTION: Chronic lower back pain is a leading cause of disability and healthcare spending worldwide. Discogenic pain, pain originating from the intervertebral disk, is a common etiology of chronic lower back pain. Currently, accepted treatments for chronic discogenic pain focus only on the management of symptoms, such as pain. There are no approved treatments that stop or reverse degenerating intervertebral discs. Biologic therapies promoting disc regeneration have been developed to expand treatment options. VIADISC...
Source: Expert Opinion on Emerging Drugs - April 11, 2024 Category: Drugs & Pharmacology Authors: Jack K Tolson Robert L Menuet Gianni H Ly Benjamin A Chanes Elizabeth A Bryan Saurabh Kataria Julian Kim Shahab Ahmadzadeh Sahar Shekoohi Alan D Kaye Source Type: research
Emerging synthetic drugs for the treatment of hepatic cirrhosis: a 2024 update
Expert Opin Emerg Drugs. 2024 Apr 11. doi: 10.1080/14728214.2024.2341878. Online ahead of print.NO ABSTRACTPMID:38603460 | DOI:10.1080/14728214.2024.2341878 (Source: Expert Opinion on Emerging Drugs)
Source: Expert Opinion on Emerging Drugs - April 11, 2024 Category: Drugs & Pharmacology Authors: Jonathan A Fallowfield Maria Jimenez Ramos Source Type: research
Emerging drugs for the treatment of herpetic keratitis
Expert Opin Emerg Drugs. 2024 Apr 11:1-14. doi: 10.1080/14728214.2024.2339899. Online ahead of print.ABSTRACTINTRODUCTION: Herpes simplex keratitis stands as a prominent factor contributing to infectious blindness among developed nations. On a global scale, over 60% of the population tests positive for herpes simplex virus type-1 (HSV-1). Despite these statistics, there is currently no vaccine available for the virus. Moreover, the conventional nucleoside drugs prescribed to patients are proving ineffective in addressing issues related to drug resistance, recurrence, latency, and the escalating risk of vision loss. Hence, ...
Source: Expert Opinion on Emerging Drugs - April 11, 2024 Category: Drugs & Pharmacology Authors: Divya Kapoor Pankaj Sharma Deepak Shukla Source Type: research
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & amp; III clinical trials
Expert Opin Emerg Drugs. 2024 Apr 11:1-10. doi: 10.1080/14728214.2024.2340723. Online ahead of print.ABSTRACTINTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating lung disease with poor prognosis. Although two antifibrotics have been approved in the past decade there are no curative therapies.AREAS COVERED: This review highlights the current landscape of IPF research in the development of novel compounds for the treatment of IPF while also evaluating repurposed medications and their role in the management of IPF. The literature search includes studies found on PubMed, conference abstracts, and pr...
Source: Expert Opinion on Emerging Drugs - April 8, 2024 Category: Drugs & Pharmacology Authors: Sarah MacIsaac Dujrath Somboonviboon Ciaran Scallan Martin Kolb Source Type: research
Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & amp; III clinical trials
Expert Opin Emerg Drugs. 2024 Apr 8. doi: 10.1080/14728214.2024.2340723. Online ahead of print.ABSTRACTINTRODUCTION: Idiopathic pulmonary fibrosis (IPF) is a progressive, debilitating lung disease with poor prognosis. Although two antifibrotics have been approved in the past decade there are no curative therapies.AREAS COVERED: This review highlights the current landscape of IPF research in the development of novel compounds for the treatment IPF while also evaluating repurposed medications and their role in the management of IPF. The literature search includes studies found on PubMed, conference abstracts, and press relea...
Source: Expert Opinion on Emerging Drugs - April 8, 2024 Category: Drugs & Pharmacology Authors: Sarah MacIsaac Dujrath Somboonviboon Ciaran Scallan Martin Kolb Source Type: research
